Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination
with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients
with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.